<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 S484 IS: Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2015</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2015-02-12</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>114th CONGRESS</congress><session>1st Session</session><legis-num>S. 484</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20150212">February 12, 2015</action-date><action-desc><sponsor name-id="S260">Mr. Roberts</sponsor> (for himself, <cosponsor name-id="S317">Mr. Barrasso</cosponsor>, and <cosponsor name-id="S349">Mr. Portman</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To protect all patients by prohibiting the use of data obtained from comparative effectiveness
			 research to deny or delay coverage of items or services under Federal
			 health care programs and to ensure that comparative effectiveness research
			 accounts for advancements in personalized medicine and differences in
			 patient treatment response.</official-title></form>
	<legis-body>
 <section id="idEE64EA8E0B9C45E48B60957A0ECA0C2F" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2015</short-title></quote> or the <quote><short-title>PATIENTS Act of 2015</short-title></quote>.</text>
		</section><section id="id518805F1C3184FBDB7E38AC1395E8308"><enum>2.</enum><header>Prohibition on
			 Certain Uses of Data Obtained from Comparative Effectiveness Research;
			 Accounting for Personalized Medicine and Differences in Patient Treatment
			 Response</header>
			<subsection id="idFF5466E0B76E494DA4E87455130B7ADE"><enum>(a)</enum><header>In
 general</header><text display-inline="yes-display-inline">Notwithstanding any other provision of law, the Secretary of Health and Human Services—</text>
 <paragraph id="id24111E4BF57748A28D021F2CC9E1CEE5"><enum>(1)</enum><text display-inline="yes-display-inline">shall not use data obtained from the conduct of comparative effectiveness research, including such research that is conducted or supported using funds appropriated under the American Recovery and Reinvestment Act of 2009 (<external-xref legal-doc="public-law" parsable-cite="pl/111/5">Public Law 111–5</external-xref>) or authorized or appropriated under the Patient Protection and Affordable Care Act (<external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>), to deny or delay coverage of an item or service under a Federal health care program (as defined in section 1128B(f) of the Social Security Act (42 U.S.C. 1320a–7b(f))); and</text>
 </paragraph><paragraph id="ID59a96b9809a344eaac47c81fa5319709"><enum>(2)</enum><text>shall ensure that comparative effectiveness research conducted or supported by the Federal Government accounts for factors contributing to differences in the treatment response and treatment preferences of patients, including patient-reported outcomes, genomics and personalized medicine, the unique needs of health disparity populations, and indirect patient benefits.</text>
				</paragraph></subsection><subsection id="id066FDF71BF284CF39CF8ABF2C6363419"><enum>(b)</enum><header>Rule of
 construction</header><text>Nothing in this section shall be construed as affecting the authority of the Commissioner of Food and Drugs under the Federal Food, Drug, and Cosmetic Act or the Public Health Service Act.</text></subsection></section></legis-body></bill>


